We are live on
!
Find out more
O
OrbiMed Portfolio holdings
AUM
$5.05B
1-Year Est. Return
125.28%
This Fund
S&P 500
This Quarter
Est. Return
+16.4%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$6.8B
AUM Growth
+$1.2B
(+21%)
Cap. Flow
+$591M
Cap. Flow
% of AUM
8.68%
Top 10 Holdings %
Top 10 Hldgs %
38.38%
Holding
154
New
24
Increased
52
Reduced
26
Closed
34
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
RLYP
RELYPSA INC COM
RLYP
|
+$204M |
| 2 |
Perrigo
PRGO
|
+$111M |
| 3 |
AbbVie
ABBV
|
+$99.2M |
| 4 |
CELG
Celgene Corp
CELG
|
+$71.2M |
| 5 |
Zimmer Biomet
ZBH
|
+$70.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$169M |
| 2 |
Elevance Health
ELV
|
+$69M |
| 3 |
WCRX
WARNER CHILCOTT PLC ORD SHS CL A (IRL)
WCRX
|
+$56.2M |
| 4 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$53.1M |
| 5 |
CBST
CUBIST PHARMACEUTICALS INC
CBST
|
+$52.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 83.58% |
| 2 | Financials | 1.18% |
| 3 | Technology | 0.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Intuitive Surgical
ISRG
$128B
| $28.6M | 0.42% |
+670,500
| New | +$28.2M |
|
|
52
CALL
Perrigo
PRGO
$1.44B
| $26.9M | 0.39% |
175,000
+108,600
| +164% | +$15.7M |
|
|
NXTM
53
DELISTED
NxStage Medical Inc.
NXTM
| $26.8M | 0.39% |
2,679,216
-435,284
| -14% | -$4.94M |
|
|
ARRY
54
DELISTED
Array Biopharma Inc
ARRY
| $26.7M | 0.39% |
5,325,000
+493,400
| +10% | +$2.69M |
|
|
XNPT
55
DELISTED
XENOPORT, INC.
XNPT
| $26.4M | 0.39% |
4,590,800
+368,200
| +9% | +$1.99M |
|
|
PTLA
56
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $24.7M | 0.36% |
957,700
+630,700
| +193% | +$15.3M |
|
57
Neurocrine Biosciences
NBIX
$18.3B
| $24.6M | 0.36% |
2,631,000
+2,056,000
| +358% | +$20.1M |
|
58
Arrowhead Research
ARWR
$12.2B
| $23.1M | 0.34% |
+2,128,900
| New | +$17M |
|
|
DRTX
59
DELISTED
DURATA THERAPEUTICS INC COM STK (DE)
DRTX
| $22.8M | 0.34% |
1,785,714
| – | – |
|
60
Cerus
CERS
$577M
| $21.8M | 0.32% |
3,375,000
+817,100
| +32% | +$5.13M |
|
|
MRTX
61
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $21.2M | 0.31% |
1,274,332
+125,000
| +11% | +$2.14M |
|
|
ATRS
62
DELISTED
Antares Pharma, Inc.
ATRS
| $20.5M | 0.3% |
4,592,000
+227,000
| +5% | +$925K |
|
|
XOMA
63
DELISTED
Xoma
XOMA
| $19M | 0.28% |
141,481
+2,127
| +2% | +$214K |
|
64
Vertex Pharmaceuticals
VRTX
$124B
| $18.9M | 0.28% |
255,000
-83,000
| -25% | -$5.78M |
|
65
Medtronic
MDT
$113B
| $18.5M | 0.27% |
323,000
-87,000
| -21% | -$4.93M |
|
66
Bausch Health
BHC
$1.69B
| $18.4M | 0.27% |
157,000
+19,000
| +14% | +$2.08M |
|
67
Baxter International
BAX
$12.8B
| $17M | 0.25% |
449,204
+149,489
| +50% | +$5.42M |
|
|
LITS
68
Lite Strategy Inc
LITS
$32.9M
| $15.9M | 0.23% |
+99,475
| New | +$17M |
|
69
Cardinal Health
CAH
$54.6B
| $15.4M | 0.23% |
230,300
+41,000
| +22% | +$2.51M |
|
70
Jazz Pharmaceuticals
JAZZ
$16.1B
| $14.6M | 0.21% |
115,000
+43,000
| +60% | +$4.45M |
|
|
AMBI
71
DELISTED
Ambit Biosciences Corp
AMBI
| $14.4M | 0.21% |
1,490,769
| – | – |
|
72
MacroGenics
MGNX
$235M
| $13.5M | 0.2% |
+491,897
| New | +$12.9M |
|
|
GWPH
73
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $13.3M | 0.2% |
+320,200
| New | +$10.1M |
|
|
74
CALL
AbbVie
ABBV
$471B
| $13.2M | 0.19% |
250,000
| – | – |
|
75
Vanda Pharmaceuticals
VNDA
$303M
| $12.3M | 0.18% |
+990,000
| New | +$9.94M |
|
Similar funds
HSA
LIM
NL
BPWM
LFG
JIM
CTC
PAMP
OrbiMed's Q4 2013 Portfolio in Review
As of Q4 2013, OrbiMed held 154 positions worth $6.8B, up 21% from $5.6B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
OrbiMed deployed $591M of net new capital in Q4 2013, opening 24 new positions and adding to 52 existing holdings. Its largest new stake was RELYPSA INC COM: 9,941,549 shares worth $249M.
By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 84% a quarter earlier, followed by Financials and Technology.
On the sell side, the largest reduction was Merck, an estimated $169M trimmed.
- OrbiMed's largest Q4 2013 buy was RELYPSA INC COM: 9,941,549 shares worth $249M.
- OrbiMed added most to AbbVie in Q4 2013, an estimated $99.2M increase.
- OrbiMed's biggest Q4 2013 reduction was Merck, cutting an estimated $169M.
- OrbiMed fully exited WARNER CHILCOTT PLC ORD SHS CL A (IRL) in Q4 2013, selling an estimated $56.2M.
- OrbiMed's ten largest holdings make up 38% of its $6.8B portfolio in Q4 2013.
- OrbiMed opened 24 new positions and closed 34 in Q4 2013.
- OrbiMed's portfolio value rose 21% quarter-over-quarter to $6.8B.
Based on OrbiMed's 13F filing for Q4 2013, filed 14 Feb 2014.